LUNAPHORE
6.2.2020 11:32:13 CET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23M. The round was led by the Japanese strategic investor PHC Holdings Corporation (hereafter, PHCHD), a global healthcare company that owns Epredia, a leading provider of comprehensive solutions for precision cancer diagnostics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200206005367/en/
The closing of the oversubscribed round was finalized on January 15, 2020. Existing investors including Redalpine Venture Partners, OCCIDENT and Alpana Ventures have also participated in this financing round.
“We are thrilled by the confidence placed in Lunaphore by our existing investors as well as the new ones in this financing round. The interest of global players in healthcare, like PHCHD demonstrates the relevance and added value of Lunaphore’s technology and confirms its high potential to transform the field of tissue analytics” said Ata Tuna Ciftlik, Lunaphore’s CEO, and added “We’re one step closer to fulfilling our vision of enabling highly sophisticated new-generation tissue analytics tests with our unique automation capabilities. The expertise and rapidly expanding network of the PHC Group and the specialist knowledge of the anatomical pathology field at Epredia will both help us gain scale and speed in this process”.
Lunaphore will invest the proceeds of Series C funding in market and product expansion. This includes a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.
“We are delighted that PHCHD has invested in one of the most exciting players in tissue staining” said James Post, President of Epredia, a PHC Group portfolio company. “We believe that their technology has the potential to help revolutionize tissue analytics and greatly improve the workflow for pathologists and immuno-oncology researchers. We look forward to working together with Lunaphore to further develop their highly innovative solutions and bring them to market to help further enhance cancer research and diagnostics.” Mr. Post has joined Lunaphore’s Board of Directors as part of the transaction.
“This investment is a strong strategic fit for PHCHD, as we look to invest further in our diagnostics business,” explained Michael Kloss, President and CEO of PHCHD. “Lunaphore’s tissue staining products complement the portfolio we currently have in Epredia and we believe there is a strong opportunity for growth in their business.”
Epredia was created in June 2019 following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings Corporation. Epredia’s portfolio includes microscope slides, instruments and consumables and they are committed to providing high quality products and services to enhance precision cancer diagnostics.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies nationally and internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com
.
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with its subsidiaries including PHC Corporation, Epredia, LSI Medience Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare services. PHC Holdings Corporation group’s consolidated net sales in FY2018 was 186.8 billion yen with global distribution of products and services in more than 125 countries. For further information on PHC Holdings Corporation, please visit www.phchd.com/global
.
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. Powered by key brands, including Erie, Menzel, Microm, Shandon, and Richard Allan, Epredia’s portfolio includes microscope slides, instruments and consumables. Established following the acquisition by PHC Holdings Corporation in 2019, Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005367/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 07:30:00 CEST | Press release
Freedom Bank SuperApp to be promoted as a payment option on China’s leading e-commerce platforms through Antom On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allo
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom